MedPath

A Usability Study of External Neuromodulation With iTEAR100 Generation 2

Phase 4
Conditions
Dry Eye Syndromes
Interventions
Device: iTEAR100
Registration Number
NCT05304650
Lead Sponsor
Olympic Ophthalmics, Inc.
Brief Summary

A Usability Study of External Neuromodulation With iTEAR100 Generation 2. A study which evaluates user ability to train and access the iTEAR100 device in a telehealth environment.

Detailed Description

A Usability Study of External Neuromodulation With iTEAR100 Generation 2. A study which evaluates user ability to train and access the iTEAR100 device in a telehealth environment. Subjects sign a consent form and are sent a device. After downloading a mobile app, they can access the device and download a prescription. At 7 days, an official telehealth visit evaluates their success in the set up and training. At 30 days, the trial ends, A usability survey and symptom evaluation survey are used to determine success.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria

Able to sign English language consent form and over age 18 and reside in the U.S.

Exclusion Criteria

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
iTEAR100 TherapyiTEAR100Treatment Arm. Assessment of usability of generation 2 connected devices
Primary Outcome Measures
NameTimeMethod
Usability30 days

Subjects rate the device usability similar to daily mobile applications and home devices using a scale from -3 to +3 with 0 being same as every day devices such as bank application, restaurant application, etc.

Secondary Outcome Measures
NameTimeMethod
Adverse Events30 days

Skin Damage, Headache, Dizziness, Sneezing

Symptom Score30 Days

SPEED standard symptom score

Symptom Scores30 days

OSDI and SPEED standard symptom scores

Trial Locations

Locations (1)

Olympic Ophthalmics

🇺🇸

Issaquah, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath